Investment Analysts’ Weekly Ratings Updates for Spyre Therapeutics (SYRE)

Spyre Therapeutics (NASDAQ: SYRE) recently received a number of ratings updates from brokerages and research firms:

• 2/21/2026 – Spyre Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/20/2026 – Spyre Therapeutics had its price target raised by Wells Fargo & Company from $40.00 to $50.00. They now have an “overweight” rating on the stock.
• 2/20/2026 – Spyre Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.
• 2/19/2026 – Spyre Therapeutics was upgraded by Leerink Partners to “strong-buy”.
• 1/16/2026 – Spyre Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.
• 12/29/2025 – Spyre Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $32.80, for a total transaction of $492,000.00. Following the sale, the chief executive officer owned 657,540 shares of the company’s stock, valued at approximately $21,567,312. This trade represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 45,000 shares of company stock valued at $1,387,500 in the last 90 days. Corporate insiders own 6.20% of the company’s stock.

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.